Risk of myocardial infarction and cardiovascular death associated with inhaled corticosteroids in COPD

European Respiratory Journal

Volumn 35, Issue 5, 2010, Pages 1003-1021

  Loke, Y K ^a   Kwok, C S ^a   Singh, S ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular effects; Chronic obstructive pulmonary disease; Inhaled corticosteroids; Meta analysis; Mortality

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALMETEROL XINAFOATE; TRIAMCINOLONE;

ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; EMBASE; FOLLOW UP; HEART INFARCTION; HUMAN; MEDLINE; MORTALITY; PRIORITY JOURNAL; SMOKING; SPIROMETRY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; CARDIOVASCULAR DISEASES; HUMANS; MYOCARDIAL INFARCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY FUNCTION TESTS; RISK;

EID: 77951972998     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00095909     Document Type: Article

References (64)

1. Suissa S, McGhan R, Niewoehner D, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 535-542. (Pubitemid 47547848)
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Available from www. goldcopd.com/Guidelineitem.asp?l1=2&l2= 1&intId=2003
3. Sin DD, Paul Man SF. Cooling the fire within: inhaled corticosteroids and cardiovascular mortality in COPD. Chest 2006; 130: 629-631.
4. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008; 149: 380-390.
5. Macie C, Wooldrage K, Manfreda J, et al. Inhaled corticosteroids and mortality in COPD. Chest 2006; 130: 640-646.
6. Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol 2006; 16: 63-70.
7. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease: a meta-analysis. Arch Intern Med 2009; 169: 219-229.
8. GlaxoSmithKline clinical trials register. Result summaries: Compounds. Available from: www.gsk-clinicalstudyregister.com/result-compounds.jsp
9. Astra Zeneca Clinical Trials register. Transparency of data. Available from: www.astrazenecaclinicaltrials.com/clinicaltrials
10. Loke YK, Price D, Herxheimer A. Adverse effects. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.02. Available from: www.cochrane-handbook. org
11. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
12. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 1439-1450.
13. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ, 2003; 327: 557-560.
14. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead?, BMJ 1998; 316: 989-991. (Pubitemid 28135151)
15. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555. (Pubitemid 351650535)
16. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
17. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456. (Pubitemid 36173708)
18. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
19. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919. (Pubitemid 37540641)
20. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008; 102: 1099-1108.
21. GlaxoSmithKline. Study No. FLTA3025. Available from: www. gsk-clinicalstudyregister.com/files/pdf/1231.pdf
22. GlaxoSmithKline. Study No. SCO100250. Available from: www. gsk-clinicalstudyregister.com/files/pdf/3452.pdf
23. GlaxoSmithKline. Study No. SCO40041. Available from: www. gsk-clinicalstudyregister.com/files/pdf/21086.pdf
24. GlaxoSmithKline. Study No. SCO100470. Available from: www. gsk-clinicalstudyregister.com/files/pdf/1079.pdf
25. GlaxoSmithKline. Study No. SFCT01/SCO30002. Available from: www.gsk-clinicalstudyregister.com/files/pdf/23674.pdf
26. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003; 124: 834-843. (Pubitemid 37123298)
27. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149. (Pubitemid 46115085)
28. Lofdahl CG, Postma DS, Pride NB, et al. Possible protection by inhaled budesonide against ischemic cardiac events in mild COPD. Eur Respir J 2007; 29: 1115-1119.
29. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
30. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091. (Pubitemid 35178706)
31. Paggiaro PL, Dahle R, Bakran I, et al. Multicenter randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 1998; 351: 773-780. (Pubitemid 28112338)
32. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009; 69: 549-565.
33. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81. (Pubitemid 36150304)
34. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68: 1975-2000.
35. van der Valk P, Monninkhof E, van der Palen J, et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358-1363. (Pubitemid 35292702)
36. Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823. (Pubitemid 29251012)
37. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480-487. (Pubitemid 40814047)
38. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003; 168: 1488-1494. (Pubitemid 38037334)
39. Huiart L, Ernst P, Ranouil X, et al. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J 2005; 25: 634-639. (Pubitemid 40528755)
40. Mapel DW, Hurley JS, Roblin D, et al. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists. Respir Med 2006; 100: 595-609. (Pubitemid 43285746)
41. Mapel DW, Nelson LS, Lydick E, et al. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD 2007; 4: 127-134. (Pubitemid 47164864)
42. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003; 21: 260-266.
43. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580-584. (Pubitemid 32801660)
44. Soriano JB, Kiri VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2: 67-74.
45. Soriano JB, Vestbo J, Pride NB, et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002; 20: 819-825. (Pubitemid 35175115)
46. Tkacova R, Toth S, Sin DD. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respir Med 2006; 100: 385-392. (Pubitemid 43239872)
47. Vollmer WM, Peters D, Crane B, et al. Impact of regular inhaled corticosteroid use on chronic obstructive pulmonary disease outcomes. COPD 2007; 4: 135-142. (Pubitemid 47164867)
48. Hopewell S, Loudon K, Clarke MJ, et al. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009; 1: MR000006.
49. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003; 168: 49-53. (Pubitemid 37046632)
50. Sin DD,WuL,Anderson JA, et al. Inhaled corticosteroids andmortality in chronic obstructive pulmonary disease. Thorax 2005; 60: 992-997. (Pubitemid 41705466)
51. Yang IA, Fong KM, Sim EH, et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 2: CD002991.
52. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008; 300: 2407-2416.
53. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84: 210-215.
54. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
55. Sin DD, Man SF, Marciniuk DD, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207-1214. (Pubitemid 351860929)
56. Janda S Park K, Fitzgerald JM, et al. Statins in COPD: a systematic review. Chest 2009; 136: 734-743.
57. Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest 2009; 136: 1029-1038.
58. Postma DS, Calverley P. Inhaled corticosteroids in COPD: a case in favour. Eur Respir J 2009; 34: 10-12.
59. Suissa S, Barnes PJ. Inhaled corticosteroids in COPD: the case against. Eur Respir J 2009; 34: 13-16.
60. Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008; 31: 927-933.
61. Ford PA, Russell RE, Barnes PJ. ICS and COPD: time to clear the air. Int J Chron Obstruct Pulmon Dis 2009; 4: 289-290.
62. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009; 374: 712-719.
63. Singh S, Loke YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med 2010; 16: 118-122.
64. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD. Results from TORCH. Chest 2009; 136: 1456-1465.